Tarveda Therapeutics (Fomerly Known As Blend Therapeutics)
134 Coolidge Avenue
Watertown
Massachusetts
02472
United States
Tel: 617-923-4100
Fax: 617-923-4101
Website: http://www.blendtx.com/
Email: info@blendtx.com
66 articles about Tarveda Therapeutics (Fomerly Known As Blend Therapeutics)
-
Now in its fourth day, the American Association of Cancer Research (AACR) Annual Meeting 2018 held in Chicago, has had plenty of news, much of it preclinical or early-clinical data.
-
Tarveda Therapeutics to Present Preclinical Data on PEN-866 in Combination with PARP Inhibitors at the 2018 AACR Annual Meeting
4/17/2018
Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company discovering and developing Pentarins™ as a new class of potent and selective cancer medicines, today announced that the company will present preclinical data related to PEN-866 at the 2018 American Association for Cancer Research (AACR) Annual Meeting, occurring April 14-18, 2018 in Chicago, IL
-
Tarveda Therapeutics Appoints Brian Roberts as Chief Financial Officer
1/4/2018
Mr. Roberts has nearly 25 years of finance, capital markets and operations experience spanning the life sciences, medtech and media industries with a proven track record of delivering positive results, financing companies and driving shareholder value.
-
Tarveda Therapeutics Provides Year-End Update and Outlines Milestones for 2018
1/3/2018
Tarveda Therapeutics will provide corporate updates throughout the year at industry events. Mr. Fromkin will provide the first of these updates at 10am PST on January 10th at the 2018 Biotech Showcase.
-
Tarveda Therapeutics to Present at the 2018 Biotech Showcase
12/20/2017
Tarveda Therapeutics announced that Drew Fromkin, President and Chief Executive Officer, will present at the 10th Annual Biotech Showcase, occurring January 8-10, 2018 at the Hilton Union Square in San Francisco.
-
Tarveda Appoints Biotech Business Veteran Michael A. Metzger To Board Of Directors
6/20/2017
-
Tarveda To Provide Update On Novel Pentarin™ Programs At The 2017 BIO International Convention
6/13/2017
-
Tarveda To Present On Lead Intracellular Targeting Pentarin PEN-866 At 2017 American Association Of Pharmaceutical Scientists National Biotechnology Conference
5/1/2017
-
Tarveda To Present PEN-221 Data In Small Cell Lung Cancer Models At 2017 AACR Annual Meeting
3/28/2017
-
Tarveda To Present PEN-221 Data In Small Cell Lung Cancer Models At 2017 AACR Annual Meeting
3/27/2017
-
Massachusetts' Tarveda Secures Another $30 Million to Push Cancer Drugs Into Clinic
2/2/2017
-
Tarveda Provides Year-End Update And Outlines Milestones For 2017
1/5/2017
-
Tarveda To Present At North American Neuroendocrine Tumor Society (NANETS) Symposium
9/29/2016
-
Madrigal Wrangles Cancer Deal Worth $163 Million+ Out of Massachusetts' Tarveda
9/19/2016
-
Tarveda Therapeutics Spins Out Placon to Pursue Development of Next-Gen Cytotoxic Oncology Drugs
3/23/2016
-
Tarveda Therapeutics To Present At Cowen and Company 36th Annual Health Care Conference
2/29/2016
-
Tarveda Therapeutics Appoints Oncology Drug Development Leader Leila Alland, M.D., As Chief Medical Officer
1/27/2016
-
Blend Therapeutics Transforms into Tarveda Therapeutics and Bags $38 Million
1/27/2016
-
Blend Therapeutics Presents Preclinical Data For Lead Pentarin™ Program, BTP-277, Demonstrating Specific And Potent Tumor Cell Targeting For Small-Cell Lung Cancer
4/21/2015
-
Blend Therapeutics Presents Preclinical Data For Lead Candidate BTP-114 That Demonstrated Superiority To Cisplatin In Tumor Growth Inhibition
4/21/2015